EpiPen maker Mylan says may cut jobs

Mylan has been under investigation and faced harsh criticism over steep price increases for its life-saving EpiPen auto-injector, which is used for severe allergic reactions. Mylan has about 35,000 employees, the company's spokeswoman Nina Devlin said. The U.S. Senate Judiciary Committee in late November postponed a hearing planned on Mylan's $465 million settlement to resolve charges that it underpaid government healthcare programs by misclassifying its EpiPen treatment.